European Journal of Medicinal Chemistry p. 230 - 241 (2017)
Update date:2022-08-03
Topics:
Yang, Lingling
Ma, Xiaobo
Yuan, Chen
He, Yanying
Li, Ling
Fang, Sha
Xia, Wei
He, Tao
Qian, Shan
Xu, Zhihong
Li, Guobo
Wang, Zhouyu
Human sirtuin 2 (SIRT2) plays pivotal roles in multiple biological processes such as cell cycle regulation, autophagy, immune and inflammatory responses. Dysregulation of SIRT2 was considered as a main aspect contributing to several human diseases, including cancer. Development of new potent and selective SIRT2 inhibitors is currently desirable, which may provide a new strategy for treatment of related diseases. Herein, a structure-based optimization approach led to new 2-((4,6-dimethylpyrimidin-2-yl)thio)-N-phenylacetamide derivatives as SIRT2 inhibitors. SAR analyses with new synthesized derivatives revealed a number of new potent SIRT2 inhibitors, among which 28e is the most potent inhibitor with an IC50 value of 42?nM. The selectivity analyses found that 28e has a very good selectivity to SIRT2 over SIRT1 and SIRT3. In cellular assays, 28e showed a potent ability to inhibit human breast cancer cell line MCF-7 and increase the acetylation of α-tubulin in a dose-dependent manner. This study will aid further efforts to develop highly potent and selective SIRT2 inhibitors for the treatment of cancer and other related diseases.
View MoreJinTan Pingsheng Chemical Co.,Ltd
Contact:+86-519-82828200
Address:NO.11Danfengxilu Road,Jintan City,Jiangsu,China
Suzhou Kangrun Pharmaceutical, Inc
Contact:86-512-63912376,63913329
Address:Building 2, No. 2358 ,Chang'an Rd, Wujiang Economic Development Zone Pioneering park, china
NINGBO YINZHOU PRECISE COLOR CO.,LTD.
Contact:86-574-88139809 86-574-83033159
Address:Qiming Road,Yinzhou,Ningbo,China
Longhui qunfeng Chemical Co., Ltd
Contact:86-731-82173407
Address:South-east Industrial Park, Longhui County, Hunan Province, China
Contact:+1-973-357-0577
Address:10 Taft Rd.
Doi:10.1021/ja00767a066
(1972)Doi:10.1021/ja00764a082
(1972)Doi:10.1039/a604258i
(1997)Doi:10.1016/S0960-894X(01)00491-7
(2001)Doi:10.1016/j.nucmedbio.2021.01.001
(2021)Doi:10.1016/S0022-328X(98)00617-2
(1998)